📌 Key Takeaways
- The 125th Japan Dermatological Association (JDA) Congress convened June 11–14, 2026,
at the Kyoto International Conference Center,
chaired by Prof. Ryuhei Okuyama (Shinshu University). - Four themes dominated the accepted presentations:
GLP-1 drug effects on skin, skin microbiome, AI-assisted diagnosis,
and UV-induced DNA damage repair. - GLP-1 receptor agonists (Ozempic, Mounjaro) have formally entered
the dermatology research agenda in Japan—
skin management for cosmetic GLP-1 users is the next clinical challenge. - Basic research presented at JDA typically translates into
aesthetic clinic practice within 2–3 years.
This congress is a reliable preview of what’s coming to your clinic.
Academic dermatology conferences may seem distant from everyday skincare decisions.
But the questions they answer—
How do we correctly treat acne? How far can hyperpigmentation be reversed?
Can aging skin be regenerated?—
are precisely the questions that eventually reshape what happens in aesthetic clinics.
The 125th Congress of the Japan Dermatological Association (JDA),
held June 11–14, 2026 in Kyoto,
offered a clear signal of where dermatology science is heading.
NERO analyzed the accepted presentation topics
to identify what 2026’s dermatology agenda means for aesthetic medicine.
INDEX
Two Societies, One Pipeline: JDA and Aesthetic Dermatology in Japan
Disease mechanism research & drug development
Insurance-covered medicine
~12,000 members
Efficacy & safety of cosmetic procedures
Out-of-pocket (elective) medicine
~3,000 members
Basic research and clinical evidence presented at the JDA
typically flows into aesthetic dermatology practice
within two to three years.
Understanding what the mainstream dermatology community
is investigating today
is the most reliable way to anticipate
what aesthetic clinics will offer tomorrow.
Theme 1: GLP-1 Drugs Enter the Dermatology Research Agenda
One of the most significant shifts at this year’s congress
was the formal inclusion of GLP-1 receptor agonists—
drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide)—
as a dermatology research topic.
In the United States, Dermatologic Surgery published a landmark special issue
on June 24, 2026,
presenting the first human data showing
a roughly fourfold reduction in adipose-derived stem cells (ADSCs)
in patients using GLP-1 medications.
Japan’s dermatology community is now asking the same questions.
As GLP-1 drugs are increasingly prescribed for cosmetic weight loss in Japan’s elective medicine market,
dermatologists are beginning to address a new challenge:
how to manage skin quality—volume loss, laxity, accelerated aging—
in patients using these medications long-term.
2026 JDA Priority Themes: Reading the Accepted Presentations
Theme 4: The Science of Photoaging Strengthens the Case for Sunscreen
Research estimates that approximately 80% of visible skin aging is attributable to photoaging—primarily UVA exposure.
As dermatology science clarifies the molecular mechanisms
of UV-induced DNA damage and repair,
the scientific rationale for daily sunscreen use
shifts from cosmetic preference to medical skin protection.
This aligns with the FDA’s June 2026 approval
of bemotrizinol—a new-generation broad-spectrum UV filter—
marking a parallel advance in photoprotection science.
One of NERO’s core roles is translating
what dermatology researchers are debating in conference halls
into language that matters to real people making real decisions.
The fact that GLP-1 drugs have become a formal dermatology topic
tells us something important:
the boundary between medicine and aesthetics
is dissolving faster than most clinics are prepared for.
Knowing what dermatologists debated this year
is the most reliable way to anticipate
what your aesthetic clinic will offer next year.
- The 125th JDA Congress (June 11–14, 2026, Kyoto)
is Japan’s largest academic dermatology gathering,
chaired by Prof. Ryuhei Okuyama of Shinshu University. - The four headline themes were:
GLP-1 drug skin effects, skin microbiome,
AI-assisted diagnosis, and UV DNA damage repair. - JDA basic research reliably translates into
aesthetic clinic practice within 2–3 years.
Tracking the congress agenda is the best way
to anticipate aesthetic medicine’s next moves. - The convergence of GLP-1, microbiome science, and AI
signals that dermatology and aesthetic medicine
are integrating at an accelerating pace in 2026.
Frequently Asked Questions
such as eczema, psoriasis, and skin cancer—
typically covered by health insurance.
Aesthetic dermatologists focus on appearance-related concerns
(hyperpigmentation, wrinkles, laxity, hair removal)
through elective, out-of-pocket procedures.
In Japan, both may hold the same board certification in dermatology,
but their clinical focus differs significantly.
When choosing an aesthetic clinic,
verifying that the physician holds dermatology board certification
and maintains active research or academic involvement
is a meaningful quality indicator.
Complementary approaches include topical antioxidants
such as vitamin C, retinol, and niacinamide,
which support skin turnover and oxidative defense.
In aesthetic medicine, IPL (intense pulsed light),
picosecond lasers, and chemical peels
are used to address existing photoaging damage.
The most impactful long-term strategy, however,
is preventing UV accumulation in the first place—
consistent daily sunscreen use outperforms any corrective treatment.
AI systems for classifying hyperpigmentation types,
analyzing skin texture, and evaluating tone
are already in use at select clinics.
Academic dermatology is actively evaluating
diagnostic accuracy and appropriate clinical integration.
Broader adoption across aesthetic medicine
is expected within the next two to three years.
Sources
• 125th Japan Dermatological Association Congress Official Website (jda125.jda-conv.jp). Program overview and accepted presentation list. Published February 16, 2026.
• Nikkei Medical, “Academic Calendar: Dermatology,” June 11, 2026 (125th JDA Congress entry).
